Skip to Content
NCI Formulary
Contact NExT
Show menu
Search this site
Last Updated: 01/25/17

Information below provided by the Pharmaceutical Company.

Atezolizumab (MPDL3280A, RO5541267, TECENTRIQ®)

Agent Description

Atezolizumab is an Fc-engineered, humanized, monoclonal antibody that binds to PD-L1 and blocks interactions with the PD-1 and B7.1 receptors. Atezolizumab is a non-glycosylated IgG1 kappa immunoglobulin that has a calculated molecular mass of 145 kDa.

Mechanism of Action

Atezolizumab is a monoclonal antibody that binds to PD-L1 and blocks its interactions with both PD-1 and B7.1 receptors. This releases the PD-L1/PD-1 mediated inhibition of the immune response, including activation of the anti-tumor immune response without inducing antibody-dependent cellular cytotoxicity.


PD-L1 inhibitor

Molecular Targets



Atezolizumab is approved in the U.S. with the trade name of TECENTRIQ® for the following indications:

  • Atezolizumab is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who:
    • have disease progression during or following platinum-containing chemotherapy
    • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum containing chemotherapy
  • Metastatic non-small cell lung cancer who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving Atezolizumab.

In addition to the two FDA approved indications above, atezolizumab is also being developed both as a monotherapy and in combination with standard treatments in a number of tumor types:

  • Atezolizumab monotherapy: NSCLC, Urothelial Carcinoma (UC)
  • Atezolizumab + chemotherapy: hematologic malignancies, triple negative breast cancer, urothelial carcinoma, NSCLC, SCLC
  • Atezolizumab + radiotherapy: NSCLC, UC
  • Atezolizumab + bevacizumab: renal cell carcinoma (RCC), urothelial carcinoma, colorectal cancer (CRC)
  • Atezolizumab + cobimetinib: CRC, UC, melanoma (BRAF wild-type)
  • Atezolizumab + ipilimumab: solid tumors
  • Atezolizumab + interferon-alpha: solid tumors
  • Atezolizumab + cobimetinib & vemurafenib: melanoma (BRAF-mutant), thyroid
  • Atezolizumab + BCG: UC
  • Atezolizumab + obinutuzumab: lymphomas
  • Atezolizumab + erlotinib: NSCLC
  • Atezolizumab + alectinib: NSCLC

Package insert: External Link

Studies of Interest

Studies that may be supported:

  • tumor types not currently under study by the Pharmaceutical Company Collaborator
  • novel combinations with standard treatments not currently under study by the Pharmaceutical Company Collaborator
  • studies in relevant patient subpopulations
  • correlative studies focused on relationships between immune biology and clinical response
  • early stage studies e.g. neoadjuvant setting, in tumors not currently under study

Studies that would not be supported:

  • head-to-head studies with other PD-1/PD-L1 drugs
  • studies of novel dosing and schedules of administration
  • small under-powered randomized studies

Information collaborator would like included in investigator proposals


Genentech supports non-clinical research proposals through a separate mechanism. Please visit External Link if you wish to submit a request for a Genentech agent for non-clinical work.